Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study
Current Oncology · 2026
DOI: 10.3390/curroncol33100603 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Current Oncology, 2026. Verfasst von Zhenhong Ren und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electr…. Hauptthemen laut MEDLINE: Lung Neoplasms, Immune Checkpoint Inhibitors, Rheumatic Diseases. Die Arbeit nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Rheumatic immune-related adverse events (R-irAEs) after immune checkpoint inhibitor (ICI) therapy in lung cancer can be difficult to distinguish from cancer-related or degenerative musculoskeletal symptoms.
Methods
In this single-center retrospective cohort, we analyzed 768 ICI-treated patients and a nested questionnaire cohort to characterize rheumatologist-confirmed R-irAEs, baseline associated factors, and patient-reported outcomes. Missing baseline C-reactive protein (CRP) was handled using multiple imputation.
Results
New musculoskeletal symptoms occurred in 177 patients (23.0%), and 66 patients (8.6%) had confirmed R-irAEs. The leading phenotypes were inflammatory arthritis (n = 22), inflammatory arthralgia (n = 15), and polymyalgia rheumatica-like syndrome (n = 13). In multivariable analysis, female sex (adjusted odds ratio [OR] 2.21, 95% confidence interval [CI] 1.31–3.74), baseline CRP > 10 mg/L (OR 2.08, 95% CI 1.14–3.81), and pre-existing autoimmune disease (OR 5.24, 95% CI 2.37–11.57) were associated with confirmed R-irAEs. Among 437 questionnaire responders, confirmed R-irAEs were associated with worse pain, morning stiffness, disability, fatigue, and health status than non-confirmed musculoskeletal symptoms (all Holm-adjusted p < 0.001).
Conclusions
Confirmed R-irAEs affected a measurable minority of ICI-treated patients with lung cancer and were associated with worse post-treatment patient-reported outcomes. Because baseline patient-reported outcomes were unavailable, these findings should not be interpreted as R-irAE-attributable change.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, No. 55, Section 4, South Renmin…
- Department of Radiation Oncology, Precision Radiation in Oncology Key Laboratory of Sichuan Province, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University o…
Zitieren
APA
Ren, Z., & Lu, J. (2026). Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study. Current Oncology. https://doi.org/10.3390/curroncol33100603
Vancouver
Ren Z, Lu J. Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study. Current Oncology. 2026. doi:10.3390/curroncol33100603
BibTeX
@article{Ren2026,
author = {Ren, Zhenhong and Lu, Jianchao},
title = {Patient-Reported Burden and Clinical Spectrum of Rheumatic Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy in Lung Cancer: A Real-World Cohort Study},
journal = {Current Oncology},
year = {2026},
doi = {10.3390/curroncol33100603}
}
EUVIMED